Digestive Diseases and Sciences

, Volume 54, Issue 10, pp 2242–2246 | Cite as

Modafinil in the Treatment of Debilitating Fatigue in Primary Biliary Cirrhosis: A Clinical Experience

  • S. Ian Gan
  • Mariana de Jongh
  • Marshall M. KaplanEmail author
Original Article


Modafinil may be a potentially effective treatment for primary biliary cirrhosis (PBC)-related fatigue. About 42 patients were given a 3-day trial of 100–200 mg modafinil. Response was defined as increased energy, decreased somnolence and sleep requirements, and improved daily function. Patients with positive responses were continued indefinitely on the medication. During the initial trial period, 31 (73%) patients had complete response and continued to take the medication. Eleven (26%) had no response. In long-term follow-up (average 17.7 months), 25 (81%) patients continued to take 100–200 mg modafinil daily. Some required an increased dosage and some took the medication as needed. Four (12%) patients stopped the medication because of side-effects or reduced efficacy; one patient (3%) stopped due to medication cost and one (3%) due to resolution of fatigue. Side-effects included insomnia, nausea, nervousness, and headaches. Modafinil appears to be a safe, effective treatment for PBC-related fatigue.


Modafinil Primary biliary cirrhosis Fatigue PBC 


  1. 1.
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353(12):1261–1273.PubMedCrossRefGoogle Scholar
  2. 2.
    Borg PC, Fekkes D, Vrolijk JM, van Buuren HR. The relation between plasma tyrosine concentration and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis. BMC Gastroenterol. 2005;5:11.PubMedCrossRefGoogle Scholar
  3. 3.
    Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7(4):879–900.PubMedCrossRefGoogle Scholar
  4. 4.
    Ahboucha S, Pomier-Layrargues G, Vincent C, et al. Reduced plasma dehydroepiandrosterone sulfate levels are significantly correlated with fatigue severity in patients with primary biliary cirrhosis. Neurochem Int. 2008;52(4–5):569–574.PubMedCrossRefGoogle Scholar
  5. 5.
    Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol. 1999;11(6):623–631.PubMedCrossRefGoogle Scholar
  6. 6.
    Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102(8):1799–1807.PubMedCrossRefGoogle Scholar
  7. 7.
    Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Lindor KD. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci. 2006;51(11):1985–1991.PubMedCrossRefGoogle Scholar
  8. 8.
    Borg PC, van Os E, van den Broek WW, Hansen BE. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial. BMC Gastroenterol. 2004;4:13.PubMedCrossRefGoogle Scholar
  9. 9.
    Battezzati PM, Zuin M, Crosignani A, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther. 2001;15(9):1427–1434.PubMedCrossRefGoogle Scholar
  10. 10.
    Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther. 2006;24(5):813–820.PubMedCrossRefGoogle Scholar
  11. 11.
    Theal JJ, Toosi MN, Girlan L, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology. 2005;41(6):1305–1312.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology. 1999;117(5):1173–1180.PubMedCrossRefGoogle Scholar
  13. 13.
    Kaplan MM, Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med. 2005;143(7):546–547.PubMedGoogle Scholar
  14. 14.
    Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;25(4):471–476.PubMedCrossRefGoogle Scholar
  15. 15.
    Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology. 2006;44(1):91–98.PubMedCrossRefGoogle Scholar
  16. 16.
    Scammell TE, Matheson J. Modafinil: a novel stimulant for the treatment of narcolepsy. Expert Opin Investig Drugs. 1998;7(1):99–112.PubMedCrossRefGoogle Scholar
  17. 17.
    Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000;14(1):53–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol. 2002;13(2):105–115.PubMedGoogle Scholar
  19. 19.
    Jasinski DR, Kovacević-Ristanović R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol. 2000;23(3):149–156.PubMedCrossRefGoogle Scholar
  20. 20.
    Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2007;33:1477–1502.PubMedCrossRefGoogle Scholar
  21. 21.
    Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol. 2003;26(5):252–257.PubMedCrossRefGoogle Scholar
  22. 22.
    Czeisler CA, Walsh JK, Roth T, et al. US Modafinal in shift work sleep disorder associated with shift-work sleep disorder. N Engl J Med. 2005;353(5):476–486.PubMedCrossRefGoogle Scholar
  23. 23.
    Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005;28(4):464–471.PubMedGoogle Scholar
  24. 24.
    Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS; a randomized placebo-controlled double-blind study. Neurology. 2005;64(7):1139–1143.PubMedGoogle Scholar
  25. 25.
    Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatr. 2005;76(12):1636–1639.PubMedCrossRefGoogle Scholar
  26. 26.
    Thase ME, Fava M, De Battista C, Arora S, Hughes RJ. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11(2):93–102.PubMedGoogle Scholar
  27. 27.
    Schwartz JR, Feldman NT. Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry Clin Neurosci. 2005;17:405–412.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • S. Ian Gan
    • 1
  • Mariana de Jongh
    • 1
  • Marshall M. Kaplan
    • 1
    Email author
  1. 1.Division of GastroenterologyTufts Medical CenterBostonUSA

Personalised recommendations